bpc-157 injection site guidelines Subcutaneous Injection Sites and Instructions for Safe Self-Administration NBC News | The claims

Important Safety Information Do not use AOD-9604 if you: Have a known hypersensitivity to growth hormone fragments or any component of the formulation Have active malignancy (cancer that is currently being treated or monitored) Are pregnant or breastfeeding (insufficient safety data) Have a history of severe allergic reactions to peptide therapies Common side effects (typically mild and transient): Headache, mild gastrointestinal disturbances (flatulence, mild diarrhea at higher doses), upper respiratory tract symptoms, injection site reactions (redness, mild discomfort) Seek medical attention if you experience: Signs of allergic reaction (hives, difficulty breathing, swelling of face or throat), persistent gastrointestinal symptoms, unexplained significant changes in energy, mood, or physical symptoms Clinical Safety Data Safety studies involving approximately 900 participants across six randomized controlled trials documented that AOD-9604 displayed a very good safety and tolerability profile indistinguishable from placebo across most parameters

Not for diagnostic or therapeutic applications

However, this requires personalized care tailored to your individual risk factors, health history, and family background - not a one-size-fits-all approach

Maybe people who have some issues have hyper reactions and they produce more antibodies

Code 0438T was established to report injection of biodegradable material between the prostate and rectum, in order to protect the rectum during radiation treatment of prostate cancer